MedTrace Logo

"IL-1β Blockade to Prevent Immunothrombosis in Recipients of a Pancreatic Organ"

NCT07503834 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-03-31

No results posted yet for this study

Summary

A prospective, open-label, uncontrolled, non-randomized, single-center Phase I/II clinical trial evaluating the safety of Anakinra in the immediate post-transplant period following pancreatic transplantation

Conditions

  • Pancreatic Transplant

Interventions

DRUG

Anakinra 100Mg/0.67Ml Inj Syringe

Safety of Anakinra in the immediate aftermath of pancreatic transplantation

Sponsors & Collaborators

  • Nantes University Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2028-11-01
Completion
2029-11-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07503834 on ClinicalTrials.gov